Benchmark against your competition
Understand how AI crawlers access your site
See where AI gets info about you
Track the queries mentioning your brand
Own your AI narrative
Add GEO to your service offerings
Get recommended in shopping queries
Monitor AI mentions at scale
Cyteir Therapeutics
What AI says about Cyteir Therapeutics
Cyteir is dedicated to developing innovative therapies for cancer, specifically through their investigational drug CYT-0851. The company is currently prioritizing the development of this drug in combination with other treatments for advanced ovarian cancer.
Is this your brand?
Claim this profile to keep your information accurate and add what's missing.
Not in this profile yet:
Products & Services
CYT-0851
An oral investigational drug that inhibits monocarboxylate transporters, currently in clinical trials for advanced ovarian cancer.
Common Questions
What is CYT-0851?
CYT-0851 is an oral investigational drug developed by Cyteir that targets monocarboxylate transporters to treat cancer.
What type of cancer is Cyteir focusing on?
Cyteir is currently focusing on advanced ovarian cancer in its clinical trials.
Is there a clinical trial for CYT-0851?
Yes, there is an ongoing Phase 1/2 clinical trial for CYT-0851 in combination with capecitabine and gemcitabine.